This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.
Trotz wirksamer therapeutischer Möglichkeiten bestehen bei der Behandlung von Patienten mit mittelschwerer bis schwerer Plaque-Psoriasis und/oder Psoriasis-Arthritis (PsA) große Defizite: Die...
More than 300 delegates and 36 speakers, representing Europe, America, the Middle East, Canada, Africa, Asia and Australia, convened in Berlin, Germany, in March 2015 for Smith & Nephew’s 6th...
Atopic dermatitis (AD) poses an enormous global burden, affecting 15–20% of children and 1–3% of adults worldwide.1 In the UK alone, it is estimated that over 1.2 million children aged <12...
More than 300 delegates and 36 speakers, representing Europe, America, the Middle East, Canada, Africa, Asia and Australia, convened in Berlin in March 2015 for Smith & Nephew’s 6th...
More than 300 delegates and 36 speakers, representing Europe, America, the Middle East, Canada, Africa, Asia and Australia, convened in Berlin, Germany, in March 2015 for Smith & Nephew’s 6th...
BRAFV600-Mutation-positives fortgeschrittenes Melanom Die im November 2015 europaweit erfolgte Zulassung des selektiven MEK-Inhibitors Cobimetinib (Cotellic®) in Kombination mit dem BRAF-Inhibitor...
Die chronische spontane Urtikaria ist mit einer hohen Krankheitslast verbunden und die Standardtherapien bringen oftmals keine Linderung. Das wurde auf der Jahrestagung der European Association of...
The 2nd Spring Forum Haemophilia 2015 – ‘New Avenues in Human rFVIII Replacement: Perspectives and Challenges for the Years Ahead’– was held in Berlin, Germany, on 17 and 18 April 2015. The...
More than 300 delegates and 36 speakers, representing Europe, America, the Middle East, Canada, Africa, Asia and Australia, convened in Berlin, Germany, in March 2015 for Smith & Nephew’s 6th...
Faced with the challenge of optimising treatment for individual patients, dermatologists have to address many aspects concerning both patient and disease factors. What is the balance of risk and...